PepGen Inc.

Stage 1 · Basing · week 15

As of Oct 22, 2026, PepGen is in Stage 1, the basing phase, now in week 15 (since Jul 10, 2026). It closed at $2.70, 62.3% below its 52-week high and below its 200-day average, which is falling.

$2.70

-0.74% today

$187M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Basing, not in an uptrend yet

Setup score

—

Momentum

Steady

Edge

—

Is PEPG early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 17w

S4 41w

S2 24w

S1 15w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 17w → S1 9w → S2 12w → S3 4w → S2 9w → S3 5w → S4 41w → S1 2w → S4 10w → S1 2w → S2 24w → S3 6w → S4 10w → S1 15w current

Total tracked: 166 weeks across 14 stage runs.

PEPG among Biotechnology337th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…337	PEPGPepGen Inc.	Stage 1 · wk 15	26	−0.7%

vs 52W High

-62.3%

$1.35 lo$7.17 hi

62.3% below 52W high

Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.

Stage Maturity

Week 15

1w13w26w

Week 15, base building

How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.

vs 200 DMA

-14.1%

200 DMA: $3.14 · sloping down

Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.

Rel Volume

1.24x

vs 50-day avg

Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-0.7%

+39.9%

+69.8%

YTD

-62.3%

-44.7%

Scan Membership

Breakout Watch

Latest: 2024-06-07

4 appearances in last 60 days. First seen: 2023-02-22.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S1

Wk 15 · Vol 1.24x

2026-10-21S1

Wk 15 · Vol 1.40x

2026-10-20S1

Wk 15 · Vol 3.39x

2026-10-19S1

Wk 15 · Vol 1.26x

2026-10-16S1

Wk 14 · Vol 1.30x

2026-10-15S1

Wk 14 · Vol 0.83x

2026-10-14S1

Wk 14 · Vol 1.01x

2026-10-13S1

Wk 14 · Vol 1.36x

2026-10-12S1

Wk 14 · Vol 0.35x

2026-10-09S1

Wk 13 · Vol 0.68x

2026-10-08S1

Wk 13 · Vol 0.95x

2026-10-07S1

Wk 13 · Vol 0.72x

Moving averages & range

50 DMA

$2.82

200 DMA

$3.14

52W High

$7.17

52W Low

$1.35

5D Low

$2.60

Resistance levels (recent highs)

20d High

$2.87

60d High

$3.43

120d High

$3.43

250d High

$7.17

Next resistance

+6.3%

to 20d High

ROE

-75.5%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.6

PepGen: quick answers

What stage is PepGen in?

As of Oct 22, 2026, PepGen (PEPG) is in Stage 1, the basing phase. It entered Stage 1 on Jul 10, 2026 and is in week 15. What the four stages mean

Is PepGen in an uptrend?

Not yet. PepGen is in Stage 1, a base that can come before an uptrend. It trades 14.1% below its 200-day average, which is falling.

How far is PepGen from its 52-week high?

PepGen closed at $2.70 on Oct 22, 2026, 62.3% below its 52-week high of $7.17. Its 52-week low is $1.35.

How has PepGen performed over the past year?

As of Oct 22, 2026, PepGen is down 44.7% over the past year and down 62.3% so far in 2026.

Which sector and industry is PepGen in?

PepGen is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.